Paradigm Biopharmaceuticals Ltd has released a press release.
PAR Selects Advanced Clinical as CRO for Phase 3
Filed with ASX ·
6ix hasn’t read this filing yet.
Paradigm Biopharmaceuticals Ltd. on 6ix
Earlier from Paradigm Biopharmaceuticals
- Quarterly Activities/Appendix 4C Cash Flow Report
- Paradigm Receives $6.3m R&D Tax Refund
- PAR Capital Raising Presentation
- Successful Completion of $16M Placement for Phase 3
- Trading Halt
Later from Paradigm Biopharmaceuticals
- Loyalty and Piggyback Options Program
- Paradigm Secures Ethics Approval for Phase 3 Trial
- S&P DJI Announces March 2025 Quarterly Rebalance
- March 2025 Quarterly Activities Report & Appendix 4C
- PAR Receives US Ethics Approval for Phase 3
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals